Sinotherapeutics Inc. A

Suntech Medical disclosed its 2026 semi-annual report on the evening of August 27. In the first half of the year, it achieved operating revenue of 191 million yuan and net profit attributable to the parent company of 29.7 million yuan. Product sales revenue was 130 million yuan, while CRO and CMO business revenue was 37.36 million yuan. Among core products, sales revenue from dapagliflozin metformin extended-release tablets continued to climb, sevelamer carbonate tablets accelerated volume growth thanks to centralized procurement advantages, ursodeoxycholic acid capsules were selected for the national centralized procurement follow-up program, and olaparib tablets began implementing the results of the eleventh batch of centralized procurement in February. On the international front, multiple products received approvals from overseas drug regulators in the first half of the year, including vitamin K1 tablets approved by the U.S. FDA, enzalutamide tablets approved by China's NMPA, and posaconazole enteric-coated tablets obtaining marketing authorization in five countries through the EU decentralized procedure. In July, sevelamer carbonate tablets were approved by Malaysia's NPRA. In addition, the company signed an exclusive commercialization license agreement with Kexing Pharmaceutical for tofacitinib citrate extended-release tablets, and the product was shipped to the United States for launch in June. The CRO and CMO business added eight new collaboration projects and five new clients, bringing the cumulative number of innovative drugs supported to market approval to seven. The company said it will continue to drive volume growth for core domestic products, strengthen its one-stop platform, and deepen global industry cooperation.

Suntech Medical announced that its product Isavuconazonium Sulfate for Injection and the co-developed product Enzalutamide Tablets have been tentatively selected in the 12th National Centralized Drug Procurement. Isavuconazonium Sulfate for Injection is indicated for invasive aspergillosis and invasive mucormycosis, with the tentatively selected specification being one vial per box. Enzalutamide Tablets are indicated for prostate cancer-related conditions, with tentatively selected specifications including 40-milligram packs of 56 tablets and 80-milligram packs of 28 tablets. The procurement cycle runs from the implementation date of the selection results until December 31, 2029, during which medical institutions will prioritize the use of the winning drugs and ensure the fulfillment of agreed procurement volumes. The company stated that if subsequent procurement contracts are signed and implemented, it will help expand product sales scale, increase market share, and promote the development of the domestic market.